Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Aug. 8, 2014—In this white paper, SeraCare Life Sciences notes that “every laboratory must ask what are the appropriate [quality control] goals and what are the most cost-effective ways to achieve these goals.” The paper reviews how often to run controls, how many replicates to run, and covers useful ways to plot assay QC in real time. Read.
Aug. 8, 2014—Randy German, MT(ASCP), blood bank and laboratory quality manager at Hoag Memorial Hospital, will share best practices for nonconforming event and blood product deviation reporting and investigation in a 50-minute webinar hosted by Nouvation, maker of occurrence-tracking software. German will review regulatory requirements, discuss what should be reported, and explain effective root-cause analysis in a blame-free culture. To register, fill out this contact form and note your interest in the Sept. 24, 2014, webinar in the question field
Aug. 6, 2014—A two-day online conference Aug. 20-21 will cover a wide range of topic in genetics and genomics, such as RNAi, next-generation sequencing, genotyping, and molecular diagnostics. The meeting—sponsored by Thermo Fisher Scientific, Beckman Coulter, Roche, and other firms—will feature interactive, live streaming video sessions and a virtual exhibit floor. Faculty includes experts from MD Anderson Cancer Center, Dartmouth, and Stanford. Free CME, CE, and CEU credits are available. Register.
July 10, 2014—Instrumentation Laboratory is presenting two, hour-long educational sessions at the AACC’s Annual Meeting and Clinical Lab Expo. The first will feature Ted E. Warkentin, MD, and Pau Bruguera, PhD, on clinical and laboratory aspects of heparin-induced thrombocytopenia diagnostics (register). In the other workshop, Sharon Ehrmeyer, PhD, MT(ASCP), will talk about how to develop and implement individualized quality-control plans in POC testing (register).
June 2014—The Food and Drug Administration on April 24 approved use of the Roche Cobas HPV test as a primary standalone screen for cervical cancer in women 25 and older. CAP TODAY writer William Check, PhD, asked questions of Thomas S. Lorey, MD, medical director, TPMG Regional Reference Laboratory, Kaiser Permanente Northern California. Their questions and answers follow. For a discussion of the ATHENA data on which the FDA based its decision, see Dr. Check’s June story “Data spark new directions in cervical cancer.”
May 12, 2014—Sylvia L. Asa, MD, PhD, reviews her role in forming a pathology “dream team” at Toronto’s University Health Network to ensure the right pathologist sees the right specimen at the right time. Flexible staffing models, hospital partnerships, and technology adoption are key to innovating in diagnostics, she says. Watch the video.
May 7, 2014—CAP members should now complete the 2014 CAP Practice Characteristics Survey (PCS), if you haven’t done so already. Results from the survey will help the College set advocacy priorities and outline regional market pressures and environmental changes impacting the individual pathologist. After completing the survey, participants will be entered in a weekly prize drawing.
An expert on the diagnostic evaluation and management of hemorrhagic and thromboembolic disorders will explain one way to optimize efficiency and outcomes with regard to laboratory monitoring of heparin therapies. The April 30 event is free. Register.
An Applied Spectral Imaging April 8 webinar explains the company’s product, Tissue Match, in which a pathologist uses a brightfield H&E or IHC review to mark the exact region of interest for FISH scanning. The FISH technician then knows the exact area to analyze. Read more on how to register.
A review paper released by cancer diagnostics firm Dako aims to provide prostate pathologists a comprehensive reference on the use of various prostate markers, as well as their limitations. Download the paper.
